These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 22225955

  • 1. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι.
    Sajan MP, Nimal S, Mastorides S, Acevedo-Duncan M, Kahn CR, Fields AP, Braun U, Leitges M, Farese RV.
    Metabolism; 2012 Apr; 61(4):459-69. PubMed ID: 22225955
    [Abstract] [Full Text] [Related]

  • 2. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.
    Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR, Nimal S, Choi CS, Kim S, Shulman GI, Kahn CR, Braun U, Leitges M.
    J Clin Invest; 2007 Aug; 117(8):2289-301. PubMed ID: 17641777
    [Abstract] [Full Text] [Related]

  • 3. Insulin signalling in hepatocytes of humans with type 2 diabetes: excessive production and activity of protein kinase C-ι (PKC-ι) and dependent processes and reversal by PKC-ι inhibitors.
    Sajan MP, Farese RV.
    Diabetologia; 2012 May; 55(5):1446-57. PubMed ID: 22349071
    [Abstract] [Full Text] [Related]

  • 4. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.
    Sajan MP, Ivey RA, Farese RV.
    Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696
    [Abstract] [Full Text] [Related]

  • 5. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity.
    Sajan MP, Standaert ML, Nimal S, Varanasi U, Pastoor T, Mastorides S, Braun U, Leitges M, Farese RV.
    J Lipid Res; 2009 Jun; 50(6):1133-45. PubMed ID: 19202134
    [Abstract] [Full Text] [Related]

  • 6. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
    Sajan MP, Lee MC, Foufelle F, Sajan J, Cleland C, Farese RV.
    Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PKCλ haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes.
    Sajan MP, Ivey RA, Lee M, Mastorides S, Jurczak MJ, Samuels VT, Shulman GI, Braun U, Leitges M, Farese RV.
    Mol Endocrinol; 2014 Jul; 28(7):1097-107. PubMed ID: 24877563
    [Abstract] [Full Text] [Related]

  • 9. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.
    Sajan MP, Ivey RA, Lee MC, Farese RV.
    J Lipid Res; 2015 Jan; 56(1):70-80. PubMed ID: 25395359
    [Abstract] [Full Text] [Related]

  • 10. Metformin action in human hepatocytes: coactivation of atypical protein kinase C alters 5'-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression.
    Sajan MP, Ivey RA, Farese RV.
    Diabetologia; 2013 Nov; 56(11):2507-16. PubMed ID: 23933835
    [Abstract] [Full Text] [Related]

  • 11. Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer's disease.
    Sajan MP, Hansen BC, Higgs MG, Kahn CR, Braun U, Leitges M, Park CR, Diamond DM, Farese RV.
    Neurobiol Aging; 2018 Jan; 61():225-237. PubMed ID: 29032894
    [Abstract] [Full Text] [Related]

  • 12. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC.
    Sajan MP, Bandyopadhyay G, Miura A, Standaert ML, Nimal S, Longnus SL, Van Obberghen E, Hainault I, Foufelle F, Kahn R, Braun U, Leitges M, Farese RV.
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E179-92. PubMed ID: 19887597
    [Abstract] [Full Text] [Related]

  • 13. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.
    Farese RV, Sajan MP, Standaert ML.
    Exp Biol Med (Maywood); 2005 Oct; 230(9):593-605. PubMed ID: 16179727
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
    Sajan MP, Standaert ML, Rivas J, Miura A, Kanoh Y, Soto J, Taniguchi CM, Kahn CR, Farese RV.
    Diabetologia; 2009 Jun; 52(6):1197-207. PubMed ID: 19357831
    [Abstract] [Full Text] [Related]

  • 16. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity.
    Sajan MP, Acevedo-Duncan ME, Standaert ML, Ivey RA, Lee M, Farese RV.
    Diabetes; 2014 Aug; 63(8):2690-701. PubMed ID: 24705403
    [Abstract] [Full Text] [Related]

  • 17. Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota.
    Standaert ML, Ortmeyer HK, Sajan MP, Kanoh Y, Bandyopadhyay G, Hansen BC, Farese RV.
    Diabetes; 2002 Oct; 51(10):2936-43. PubMed ID: 12351430
    [Abstract] [Full Text] [Related]

  • 18. Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B.
    Sajan MP, Leitges M, Park C, Diamond DM, Wu J, Hansen BC, Duncan MA, Apostolatos CA, Apostolatos AH, Kindy M, Farese RV.
    Curr Alzheimer Res; 2021 Oct; 18(12):941-955. PubMed ID: 34951366
    [Abstract] [Full Text] [Related]

  • 19. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV.
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [Abstract] [Full Text] [Related]

  • 20. Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status.
    Farese RV, Sajan MP.
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E385-94. PubMed ID: 19996389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.